MPS NEW

Current Pharmaceutical Design

Journal Impact Factor: 2.8

Scopus Cite Score: 5.9

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed

View All

Aims and Scope:

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Editor-in-Chief:

Alessandro Antonelli Department of Clinical and Experimental Medicine
University of Pisa
Pisa
Italy

ISSN: 1381-6128 (Print)

eISSN: 1873-4286 (Online)

Special Issues With Active Call for Papers

Submission closes on: Oct 23, 2026

Mapping Dynamic Sites and Designing Novel Therapeutics

The concept of allostery, where ligand binding at a site distinct from the active or orthosteric site modulates protein function, has emerged as a transformative paradigm in modern drug discovery. Unlike conventional orthosteric drugs that often face limitations in selectivity and off-target effects, allosteric modulators offer a promising alternative. Their inherent specificity, arising from the unique and less conserved nature of allosteric pockets, enables fine-tuned regulation of protein activity with minimal disruption to essential physiological... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Mingkai Li
Co-Guest Editor(s): Lei Zhang,Prof. Lina Chen

Start Submission

Submission closes on: Oct 16, 2026

The New Challenges of Precision Medicine for the Treatment of Thyroid Cancer

Thyroid cancer is a highly diffuse endocrine tumor whose incidence is worldwide rising. The most common histotype is the differentiated thyroid cancer (DTC), which includes the papillary thyroid cancer (PTC) and the follicular thyroid cancer (FTC). The prognosis for most of the DTC patients is favorable; however, tumors can dedifferentiate into more aggressive types not responding to conventional therapies. Therefore, for the most aggressive tumors, new therapies are needed, and the translational approach aids in... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Giusy Elia
Co-Guest Editor(s): Silvia Martina Ferrari,Poupak Fallahi,Francesca Ragusa

Start Submission

Submission closes on: Sep 05, 2026

Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention

Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and heart disease. Deep learning in medical imaging has the potential to equal or surpass the skills of experienced clinicians, making the diagnosis of tumors, Alzheimer's,... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Ajay Kumar

Start Submission

Submission closes on: Jul 31, 2026

Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods

Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules interact, improve drug candidates, and evaluate toxicity, which reduces the need for expensive and lengthy lab experiments. In silico methods, like molecular docking and virtual screening, mimic how drugs... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Dileep Kumar

Start Submission

Submission closes on: Jul 16, 2026

Artificial Intelligence and Computational Approaches in Drug Discovery

Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, accelerating the identification of research-worthy molecules and privileged scaffolds. Concurrently in molecular design, molecular generative models and 3D structure generation technologies facilitate the rational creation... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Yang Zhang
Co-Guest Editor(s): Dr. Yuwei Wang

Start Submission

Submission closes on: May 09, 2026

Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery

The process of developing a drug is time and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc, has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, several medicinal approaches/strategies from various fields are needed. In this view, the creation of effective drugs against the target site would require the incorporation of... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Smriti Sharma
Co-Guest Editor(s): Dr. V. Murugesan

Start Submission

Submission closes on: Apr 23, 2026

Rationale Approach for Nutraceutical Discovery, Development, and Delivery for Chronic Disease Management

The increasing burden of chronic diseases, such as cardiovascular disorders, diabetes, neurodegenerative diseases, inflammatory conditions, and cancer, has driven the demand for alternative and adjunctive therapeutic strategies. Nutraceuticals, derived from functional foods, dietary supplements, herbal extracts, and bioactive compounds, offer multi-targeted mechanisms, minimal side effects, and potential synergies with conventional pharmaceuticals. This thematic issue aims to explore innovative approaches in nutraceutical discovery, formulation strategies, application of nanotechnology, clinical validation, and ethical and regulatory aspects. Special... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Manish Kumar Jeengar
Co-Guest Editor(s): Dr. Shafiul Haque,Prof. Dr. Kaladhar Kamalasanan,Dr. Jitendra Gour

Start Submission

Submission closes on: Apr 13, 2026

The Bidirectional Interaction Between Cancer and Cardiovascular Disease

Cancer and cardiovascular disease (CVD) are the two leading causes of morbidity and mortality worldwide. Emerging evidence highlights a complex and bidirectional relationship between these conditions. Cancer therapies, including chemotherapy, radiotherapy, targeted therapies, and immunotherapies, are associated with increased cardiovascular toxicity. Conversely, pre-existing cardiovascular conditions can significantly influence cancer treatment outcomes and overall survival. Moreover, shared risk factors such as inflammation, metabolic dysregulation, aging, and lifestyle factors further complicate this interplay. This thematic issue aims... see more

Impact Factor: 2.8
Guest Editor(s): Dr. Nicola Cosentino

Start Submission

Submission closes on: Mar 05, 2026

Synopsis on Design, Development, and Evaluation of Novel Therapeutics in Pediatrics

The field of paediatric therapeutics is evolving rapidly, driven by advances in drug design, precision medicine, and novel delivery systems tailored to children’s unique physiological and developmental needs. This special issue aims to comprehensively overview emerging strategies for discovering, formulating, and clinically assessing new paediatric treatments globally. see more

Impact Factor: 2.8
Guest Editor(s): Dr. Mohammad Amjad Kamal
Co-Guest Editor(s): Dr. Badriyah Alotaibi

Start Submission

Submission closes on: Jan 15, 2026

Management Of Primary And Metastatic Hepatic And Biliary Cancer

Cancer of the liver (primary and metastatic) and of the biliary tract is common wordwide. The pathophysiology is diverse. The therapeutic measures for the cancer of the liver and biliary tract include chemotherapy, surgery, transplantation, radiotherapy, immunotherapy and others. The aim of this thematic issue is to summarize the state-of-the-art for the therapeutic management of the cancer of the liver and biliary tract. see more

Impact Factor: 2.8
Guest Editor(s): Dr. Márcio Fernandes Chedid

Start Submission